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Abstract: A general, five step method for the synthesis of 3-alkylfentanyl analogues (i.e., cis
and trans 3-alkyl-4-anilidopiperidines 6.1–6.6) has been developed. The starting N-phene-
thyl-4-piperidone 1 was first converted into the cyclohexylimine derivative 2, -deprotonated
with butyllithium and the resulting imine anion efficiently monoalkylated with primary and
secondary alkyl halides. After mild acid hydrolysis, the obtained 3-alkyl-4-piperidones
3.1–3.6 were isolated in good yields (79–85 %), then condensed with aniline to form imines
4.1–4.6. Subsequent reduction of the imines (LiAlH4/THF) yielded cis/trans mixtures of
3-alkyl-4-anilinopiperidines 5.1–5.6. Quantitative separation of the diastereoisomers by col-
umn chromatography of Al2O3 gave pure cis 5.1–5.6 (29–51 % yield) and trans 5.1–5.6
(19–27 % yield), with the cis/trans ratio in the range 7/3–6/4. The synthesis was concluded by
N-acylation of the purified 5.1–5.6, with propionyl chloride, to afford cis and trans 3-al-
kyl-4-anilidopiperidines 6.1–6.6 ( 95 % yield, as monooxalate salts). No enatioseparation
was attempted at any stage. The relative cis/trans stereochemistry was provisionally assigned
from the 1H-NMR spectra. Of the twelve synthesized 3-alkylfentanyls, ten compounds (two
known and eight novel derivatives, all as the monooxalate salts) were preliminarily tested as
analgesics in rats, comparing the potency to fentanyl. Except for the known ()-cis-3-Me
fentanyl 6.1cis, (8  fentanyl), and the novel ()-cis-3-Et fentanyl 6.2cis, (1.5  fentanyl), all of
the others were less active than fentanyl or inactive. Some tentative conclusions on the struc-
ture-activity relationship (SAR) in this series of derivatives have been made.
INTRODUCTION
The exceptional opioid analgesic activity of 4-anilidopiperidines (general structure I,
Scheme 1) has been well documented in the past forty years.1 Clinically successful drugs,
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fentanyl II,2 (a 50–100 times more potent analgesic in humans than morphine), sufentanil
III,2 ( 6  fentanyl3), alfentanil IV,2 ( 0.13  fentanyl4) and remifentanil V,2 ( 2.5–5 
fentanyl
5) have been used extensively. Combined with various anesthetics, they have been
employed in most of the major and minor surgeries, under the general anesthesia. Fentanyl
and its derivatives are also widely used in conscious patients, to manage postoperative pain,
in obstetrics and during various orthopedic interventions. Fentanyl transdermal patches
(Duragesic®), with controlled drug release over several days, serve to control chronic cancer
pain.6 Carfentanil VI ( 20–30  fentanyl1a) is a veterinary analgesic, used to sedate wild ani-
mals.7 Numerous fentanyl analogues have been synthesized,8 as potential candidates for
novel drugs, in order to establish the structure-activity relationship (SAR) and to probe the
opioid receptors. Isotopically labelled fentanyl derivatives have been employed in opioid re-
ceptor studies, both in vitro and in vivo. For example, positron emission tomography, (PET),
with 11C labelled carfentanyl, has been used in healthy volunteers to observe the opioid re-
ceptor distribution in the body organs and other receptor properties.9
Some thirty years ago it was disclosed that a methyl group introduced in the position 3
of the piperidine ring may dramatically enhance the activity, depending on the relative and
the absolute stereochemistry.10 Thus (+)-cis-3-Me fentanyl VII (19  fentanyl) is ca. 100
times more potent as the (–)-enantiomer. The corresponding racemic trans isomer is ap-
proximately as active as fentanyl.10b Of the other 3-alkyl derivatives, only 3-Pr and 3-allyl
analogues have been prepared up to the present11 (Table II). Also, in an earlier work,
3-methoxycarbonyl fentanyl was synthesized.8c
These facts prompted us to prepare several novel 3-alkylfentanyl derivatives (general
structure 6, Scheme 2) and to establish the correlation between the structure (including
stereochemistry) of the 3-alkyl group and the analgesic activity.
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Scheme 1.
RESULTS AND DISCUSSION
The five step synthesis, starting from piperidone 1, is outlined in Scheme 2. The req-
uisite piperidones 3.1–3.6 were prepared by a modification of a general method for the
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Scheme 2.
monoalkylation of carbonyl compounds via the imine or hydrazone derivatives.12 Con-
densation of 1 and cyclohexylamine under azeotropic water separation gave imine 2. The
completion of the reaction was determined by IR spectroscopy (absence of the carbonyl
band at 1710 cm–1, presence of the imine band at 1665 cm–1).
Deprotonation of 2 with butyllithium (THF, 10º) proceeded rapidly (like a titration)
and quantitatively, yielding a bright, orange-red solution of the imine anion. No 1,2-addi-
tion reaction of butyllithium to the ketimine group was observed, as hydrolysis of the anion
recovered only the starting piperidone 1. The use of LDA instead of butyllithium was
equally effective but offered no advantage in terms of the yields and purity of the products.
The imine anion reacted rapidly with primary and secondary alkyl halides, MeI, EtI, i-PrI,
BuBr and phenethyl bromide (PhenBr), to yield only the monoalkylated imine intermedi-
ates. Completion of the alkylation is observable visually, since the orange-red coloration of
the anion changes to pale yellow. The imines are hydrolysed completely in situ, by the ad-
dition of an aqueous NaH2PO4 solution (pH  5–6), to afford good yields (79–85 %) of the
corresponding 3-alkylpiperidones 3.1–3.6. Only in the case of the 3-i-Pr derivative, the hy-
drolysis required lower pH (dil. HCl), apparently due to steric hindrance. Importantly, the
obtained ketones were pure ( 95–98 %), containing neither polyalkylated products nor
the starting piperidone 1 (0–3 %, acc to cap. GC and 1H-NMR).
Conversion of piperidones 3.1–3.6 to the respective stereoisomeric 3-alkyl-4-anilino-
piperidines 5.1–5.6 was effected in two steps, via the aromatic imine intermediates 4.1–4.6.
Similar procedures were applied earlier on some related systems.13 The piperidones react
with aniline (2 eq.) relatively slowly (12–36 h, depending on the steric hindrance), requiring
boiling xylene and azeotropic water separation, as well as a Lewis acid catalyst (10 mol% of
anh. ZnCl2). In addition, the high sensitivity of the imines 4.1–4.6 to oxidative decomposi-
tion necessitates an inert atmosphere (Ar or N2). Completion of the condensation was indi-
cated by IR spectroscopy (disappearance of the carbonyl band at 1710 cm–1, appearance of
the imine band at 1660 cm–1). Monitoring the reaction by TLC, GC or HPLC was not pos-
sible due to the rapid hydrolysis or decomposition of the imine.
The crude imines, together with the residual aniline, were then reduced using LiAlH4
(4 eq. of H–). The reduction was found to be sluggish in ether, but much faster in THF.
Thus, it required  5–10 h to complete, depending on the steric hindrance of the imine.
However, the reaction conditions had not been optimised with respect to the reaction time
and the hydride mole ratio.
After the standard workup (excess hydride destruction with EtOAc and successive
treatment with aqueous acid and alkali), the isolated residues consisted of cis/trans mixtures
of the corresponding 3-alkyl-4-anilinopiperidine 5.1–5.6, aniline and small amounts of the
corresponding 3-alkylpiperidine-4-ol, (0–10 %, cis/trans mixture). The alcohols apparently
originated from a partial hydrolysis of the imine, prior to reduction. After vacuum removal of
the residual aniline and quantitative column chromatography separation on Al2O3, pure
cis-5.1–5.6 and trans-5.1–5.6 diastereoisomers were obtained in all instances.
Yields of the pure 3-alkyl-4-anilinopiperidines ranged from 29–51 % for the cis isomers
and from 19–27 % for the trans isomers, with the cis/trans ratio  7/3–6/4. Interestingly, the
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diastereoisomers could not be separated by capillary GC nor on SiO
2
plates or columns, pos-
sibly due to a stronger, specific binding of the amines to silica as compared to alumina. The
diastereoisomeric purity of 5.1–5.6 was determined to be  100 %, by 13C-NMR and
1H-NMR spectroscopy. The relative, cis/trans stereochemistry of the products was assigned
from 1H-NMR spectra of the corresponding 3-alkyl-4-anilidopiperidines 6.1–6.6. Reduction
procedures of imines 4.1–4.6 with some other reagents were examined briefly, following lit-
erature reports for related systems. Thus, reduction with NaBH3CN in MeOH or in a buf-
fered methanolic solution14 (citrate or acetate buffer, pH  5–6) produced very substantial
amounts of the corresponding 3-alkylpiperidin-4-ol, due to the rapid hydrolysis of the imines
by traces of moisture. Similarly, the alcohols predominated when reduction of the imines was
attempted with a large excess of NaBH4 in MeOH, EtOH or i-PrOH.
15 Catalytic hydrogena-
tion16 over 10 % Pd/C in MeOH, MeOH/buffer or EtOAc/AcOH, at 3–20 atm, was either
exceedingly slow or led to hydrolysis and subsequent reduction to the alcohols.
Having prepared a total of 12 diastereoisomerically pure cis and trans anilinopiperidi-
nes 5.1–5.6, the synthesis of the 3-alkylfentanyl analogues was completed by N-acylation
of the secondary amino function, using propionyl chloride (2 eq.) in CH2Cl2. Despite the
tertiary amino group in the piperidine ring serving as an HCl acceptor, it was found neces-
sary to add extra base (0.5 eq. of Et3N) to bring the reaction to completion. The obtained
cis and trans anilidopiperidines 6.1–6.6, where isolated and purified as the monooxalate
salts, precipitated from i-PrOH, Et2O, THF or EtOAc (> 95 % yields).
The relative, cis/trans stereochemistry was assigned by comparing the 1H-NMR
spectral data of cis and trans 6.1–6.6 to the published spectra10b of cis- and trans-3-Me
fentanyl 6.1, as represented in Table I. In the later instance, the absolute stereochemistry
was determined by X-ray diffraction analysis. It was established that all of the prepared
anilidopiperidines exhibit very specific 1H-NMR signals of the C4–H group in the
piperidine ring. The signals possess a distinctive multiplicity and chemical shift, depending
on the relative stereochemistry, Fig. 1. All the cis isomers, including cis-3-Me fentanyl
6.1cis, display a fully resolved doublet of triplets (Jt  4 Hz, Jd 12 Hz), except for 6.3cis,
(3-i-Pr), which shows an apparent quintet. The chemical shifts, compared to the corre-
sponding trans isomers, have uniformly lower values by  0.2 . The trans isomers show
either triplets (Jt  11–12 Hz), with additional partial splitting into doublets or fully re-
solved triplets of doublets as in the case of 6.5trans compound (3-Phen, Jd = 4 Hz, Jt = 11
Hz). Thus, the relative stereochemistry of the synthesized fentanyl derivatives may be con-
sidered as being provisionally assigned with a considerable degree of certainty.
Ten of the synthesized compounds, all in the racemic form, were tested as opioid an-
algesics (i.e., for antinociceptive activity) and compared with the potency to fentanyl.
Those included two known compounds, cis-3-Me fentanyl 6.1cis and trans-3-Me fentanyl
6.1trans, as well as eight novel derivatives: cis-3-Et fentanyl 6.2cis, trans-3-Et fentanyl
6.2trans, cis-3-i-Pr fentanyl 6.3cis, cis-3-Bu fentanyl 6.4cis, trans-3-Bu fentanyl 6.4trans,
cis-3-Bn fentanyl 6.5cis, trans-3-Bn fentanyl 6.5trans and cis-3-Phen fentanyl 6.6cis.
Wistar type rats (weighing 200–300 g) of both sexes were used in all the experiments.
The analgesic (antinociceptive) activity was assessed by measuring the warm water in-
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duced tail withdrawal reflex17 after intraperitoneal administration of the oxalate salts of the
tested compounds. Three doses of each compound were tested with 6–8 rats per dose and
the obtained dose-response curves analysed using the linear regression statistical method.
The ED50 values and the 95 % confidence limits were estimated from the dose-response
curves using a standard statistical software.18
TABLE I. 1H-NMR signals of the C4–H group of cis and trans 3-alkyl-4-anilidopiperidines 6.1–6.6.
Chemical shift in ppm, coupling constants in Hz
No. Compound 1H-NMR (C4–H signal) No. Compound
1H-NMR (C4–H signal)
1 6.1 cis (3-Me) 4.41 (dt, Jt = 4.4,
Jd = 12.6)
#
7 6.4 cis (3-Bu) 4.38 (dt, Jt = 4.5,
Jd = 12.4)
2 6.1 trans (3-Me) 4.58 (t, J = 11.4)# 8 6.4 trans (3-Bu) 4.61 (t, J = 7.0)
3 6.2 cis (3-Et) 4.40 (dt, Jt = 4.6,
Jd = 12.4)
9 6.5 cis (3-Bn) 4.49 (dt, Jt = 3.4,
Jd = 12.4)
4 6.2 trans (3-Et) 4.61 (td, Jd = 3,
Jt = 12)
10 6.5 trans (3-Bn) 4.75 (t, J = 10.0)
5 6.3 cis (3-Pr) 4.60 (quint, J = 5.0) 11 6.6 cis (3-Phen) 4.37 (dt, Jt = 4.6,
Jd = 12.6)
6 6.3 trans (3-Pr) 4.83 (td, Jd = 3.6,
Jt = 12.0)
12 6.5 trans (3-Phen) 4.64 (td, Jd = 4.0,
Jt = 11.0)
# Lit. values10b for 6.1 cis: 4.40  (dt, Jt = 5.0, Jd = 12.5); 6.1 trans: 4.53  (td, Jd = 4.5, Jt = 12.5)
The absolute analgesic (antinociceptive) potencies, expressed as the ED50 value (dose
that produced 50 % of the maximum possible antinociceptive effect), as well as the poten-
cies relative to fentanyl are presented in Table II. For comparison, the literature values for
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Fig. 1. Characteristic signals of the C4–H proton in the
1H-NMR spectra of cis-3-Me fentanyl 6.1cis and
trans 3-Me fentanyl 6.1trans. The signals are typical for all of the synthesized cis-and trans-3-alkylfentanyl
analogues, respectively.
()-cis-3-Me fentanyl 6.1cis, ()-trans-3-Me fentanyl 6.1trans, (–)-cis-3-Me fentanyl,
(+)-cis-3-Me fentanyl, ()-cis-3-allyl fentanyl, ()-cis-3-Pr fentanyl, ()-trans-3-Pr
fentanyl and morphine are also induded in Table II.
Based upon the preliminary results of the pharmacologic testing and in agreement
with the published data, summarized in Table II, some tentative conclusions on the struc-
ture-activity relationship may be put forward.
– The presence of a substituent in position 3 of the piperidine ring generally decreases
or completely inhibits the analgesic activity compared to fentanyl. Exceptions are the
(+)-cis-3-Me analogue ( 19  fentanyl) and ()-cis-3-Et fentanyl 6.2cis ( 1.5  fentanyl).
In the later instance, presumably, one of the enantiomers was much more active than the
other.
– With increasing voluminosity of the alkyl group, the potency decreases rapidly.
Thus ()-cis-3-Pr fentanyl, ()-cis-3-Bu fentanyl 6.4cis, and ()-cis-3-Bn fentanyl 6.5cis,
are 2, 16 and 126 times less potent than fentanyl, respectively. Derivatives which are even
more bulky, ()-cis-3-i-Pr fentanyl 6.3cis, and ()-cis-3-Phen fentanyl 6.6cis, are inactive
in doses up to 5 mg/kg.
– The relative cis/trans stereochemistry is important since the cis isomers are 1.5–6
times more active than the trans isomers.
– The absolute stereochemistry appears to be critical, judging from the fact that
(+)-cis-3-Me fentanyl is about 100 times more active than the (–) enantiomer.
All of the tested compounds exhibited toxic effects characteristic for the  selective
opioid agonists, (such as morphine and fentanyl), including: Straub’s tail, rigidity of the
skeletal muscles, catalepsy, loss of the corneal and righting reflexes, impaired motoric co-
ordination, and increased and/or decreased body temperature. All of the observed effects
were fully antagonized by the nonselective opioid antagonist naloxone hydrochloride
19
(1 mg/kg), corroborating the hypothesis that the tested compounds are opioid agonists,
most likely acting predominantly of  opioid receptors. The detailed pharmacological re-
sults will be published elsewhere.
In conclusion, the presented synthetic method provides access to various 3-al-
kyl-4-anilidopiperidines 6.1–6.6. The approach is relatively concise and efficient, except
for the conversion of piperidones 3.1–3.6 to the anilinopiperidines 5.1–5.6 which is tedious
and of low stereoselectivity, yielding cis/trans mixtures. However, as the diastereomeric
mixtures are fully separable by simple column chromatography, the synthesis affords pure
()-cis and ()-trans 3-alkyl-4-anilidopiperidines 6.1–6.6. The method may be useful,
inter alia, to introduce isotopically labelled groups (13C, 14C, 11C, 15N), via the corre-
sponding alkyl halides. In addition to simple alkyl groups, it is also possible to introduce
some functional groups, compatible with the strongly basic imine anion (e.g., amino, ether,
ketal, carboxylate anion).20
Pharmacological results unambiguously show that all groups in the position 3 of the
piperidine ring larger than methyl (and to a minimal extent ethyl), severely reduce the anal-
gesic potency compared to fentanyl. It is likely that the steric factor alone, rather than the
polarity and/or chemical reactivity, plays a crucial role in the pharmacological activity in
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this series. Probably the more voluminous groups prevent the ligands from forming a
sufficiently stable complex with the receptor, resulting in decreased analgesic activity.
TABLE II. Analgesic (antinociceptive) activities of 3-alkyl fentanyl analogues in the rat tail withdrawal test
after intravenous (iv) and intraperitoneal (ip) administration (all the values differ considerably in humans)
No. Compound
Route of
administration
ED50/(mg/kg)
A
(confidence limits)
Relative
potency
1 Fentanyl iv 0.011B (0.0095–0.0140) 1
ip 0.0104C (0.006–0.018) 1
2 ()-cis-3-Me Fentanyl 6.1cis iv 0.0018
B,ref 10b (0.0013–0.0024) 6.1
ip 0.0013C (0.0012–0.0014) 8
3 ()-trans-3-Me Fentanyl 6.1trans iv 0.0094
B,ref 10b (0.007–0.0127) 1.17
ip 0.00525C (0.004–0.006) 1.98
4 (–)-cis-3-Me Fentanyl iv 0.068B,ref 10b (0.051–0.091) 0.16
5 (+)-cis-3-Me Fentanyl iv 0.00058B,ref 10b (0.00049–0.00068) 18.97
6 ()-cis-3-Et Fentanyl 6.2cis ip 0.0068
C (0.0026–0.018) 1.49
7 ()-trans-3-Et Fentanyl 6.2trans ip 0.0116
C (0.011–0.012) 0.9
8 ()-cis-3-allyl Fentanyl iv 0.08
B,D,ref 11 0.138
9 ()-cis-3-Pr Fentanyl iv 0.02
B,D,ref 11 0.55
10 ()-trans-3-Pr Fentanyl iv 0.04
B,D,ref 11 0.275
11 ()-cis-3-i-Pr Fentanyl 6.3cis ip no activity in doses up to 5 mg/kg
C –
12 ()-cis-3-Bu Fentanyl 6.4cis ip 0.162
C (0.082–0.320) 0.064
13 ()-trans-3-Bu Fentanyl 6.4trans ip 0.348
C (0.181–0.669) 0.03
14 ()-cis-3-Bn Fentanyl 6.5cis ip 1.31
C (0.70–2.46) 0.0079
15 ()-trans-3-Bn Fentanyl 6.5trans ip 1.91
C (0.39–9.4) 0.0054
16 ()-cis-3-Phen Fentanyl 6.6cis ip no activity in doses up to 5 mg/kg
C –
17 Morphine iv 3.14B,D,ref 10b 286
AED50 values refer to the free bases of the tested compounds and are expressed in mg per kg of body weight;
BValues reported in the literature; CResults obtained in our laboratories; DConfidence limits not reported
EXPERIMENTAL
IR spectra were recorded on a Perkin-Elmer FT IR 1725X instrument, at 4 cm-1 resolution. 1H-NMR
and 13C-NMR were recorded on a Varian Gemini spectrometer, at 200 MHz and 50 MHz, respectively, using
CDCl3 as the solvent and TMS as the internal standard. (In some
1H-NMR spectra multiplet signals were in-
sufficiently resolved for precise integration and the number of the corresponding hydrogens could not be de-
termined. In those instances, only approximate multiplet intervals are reported). Coupling constants are given
in Hz. Mass spectra were recorded on a Finnigan-Math instrument, model 8230, employing both the electron
impact (70 eV) and chemical ionisation (with i-butane) technique. Gas chromatograms were obtained using a
Varian 3400 instrument, on a nonpolar DB-5 column. MeOH, i-PrOH, Et2O, THF, EtOAc, PhMe, hexane
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and CH2Cl2 were of p.a. grade and purified further according to standard procedures. Absolute THF and
Et2O were prepared by distillation from benzophenone/sodium. Reagents were of p.a. grade and used as sup-
plied (Aldrich Chemical Co., Merck Darmstadt Chemical Co. and Fluka Chemical Co.). Neutral Al2O3, ac-
tivity II-III, Merck, Darmstadt was used for column chromatography while thin layer plates were coated with
neutral Al2O3, HF254, Merck, Darmstadt.
1. N-[1-(2-Phenylethyl)piperidine-4-ylidenecyclohexanamine (2)
An apparatus equipped with a Dean and Stark adapter was purged with argon and charged with
piperidone 1 (10.0 g, 49 mmol), cyclohexylamine (13.8 mL, 120 mmol), p-TsOH.H2O (100 mg) and PhMe
(100 mL). The mixture was stirred magnetically and heated under reflux, with continuous water separation, for
2 h, then cooled to  20 ºC under Ar and concentrated on a rotatory evaporator. The residual imine, dark viscous
oil, is vacuum distilled (b.p. 165–170 ºC 0.1 torr). Yield: 13.52 g,  97 % (pale yellow viscous liquid). 2
hydrolyzes readily and is best kept under an Ar atmosphere. IR(cm-1): 1665 (characteristic imine band).
2. 3-Benzyl-1-phenethyl-piperidin-4-one (3.5)
A typical procedure for the preparation of 3-alkyl piperidones 3.1–3.6 is illustrated on piperidone 3.5.
The method is directly applicable to all other 3-alkyl piperidones.
A three necked flask, equipped with a pressure equalizing dropping funnel, thermometer and a reflux
condenser capped with a mineral oil bubbler was purged with Ar and charged with imine 2 dissolved in THF
(5.0 g, 17.6 mmol/40 mLTHF). Butyllithium (2.0 M in cyclohexane,  9.0 mL; 18.0 mmol) was injected into
the dropping funnel and added dropwise, over 10 min, to the cooled ( 0 ºC) and stirred mixture. An intense
yellow-orange coloration of the imine anion developed immediately. After additional stirring (15 min,  0
ºC), benzyl chloride (2.3 mL; 20 mmol/5 mL THF) was injected into the dropping funnel and then added
dropwise ( 10 min, 0–5 ºC) to the reaction mixture. The reaction was mildly exothermic, LiCl precipitated
and the yellow-orange coloration disappeared. The mixture was stirred for 1 h ( 20 ºC), then poured into
aqueous NaH2PO4
.H2O (5 g/50 mL water) and stirred for 30 min. The resulting emulsion was concentrated
using a rotatory evaporator ( 50–60 ºC). The residue was extracted with CH2Cl2 (2  50 mL), the combined
extracts dried (anh. K2CO3) and concentrated. Piperidone 3.5 was obtained as a yellow viscous oil. Yield:
4.80 g; 93 %. Purity (cap. GC):  96 %. Contamination with starting piperidone 1:  1–2 %. The compound
may be additionally purified on an Al2O3 column (30 g of alumina per 1 g of the substance) using hex-
ane/EtOAc gradient (99:1, 98:2, etc.). IR/(cm-1): 3422, 3082, 3058, 3024, 2965, 2950, 2928, 2904, 2858,
1709, 1667, 1600, 1495, 1476, 1453, 1424, 1376, 1362, 1335, 1279, 1250, 1219, 1166, 1139, 1080, 1050,
1029, 996, 889, 770, 749, 738, 723, 700; 1H-NMR (): 2.29–2.49 (m, 3H), 2.73–2.82 (m, 1H), 2.91–2.98 (m,
2H), 3.22 (d, J = 13.6, 1H), 3.40 (d, J = 12.0, 1H), 3.58–3.64 (m, 5H), 7.21–7.31 (m, 10HAr).
13C-NMR/(ppm): 32.01, 32.63, 39.54, 49.88, 52.23, 56.98, 57.71, 124.88, 124.94, 127.13, 127.17, 127.38,
127.71, 138.18, 138.66, 208.74. MS (C.I.): 294 (M+1, 100).
The same procedure was used to prepare all the other piperidones 3. The products were not purified by
chromatography.
3. ()-3-Methyl-1-phenethyl-piperidin-4-one (3.1).
From imine 2 (5.69 g, 20 mmol); Alkyl halide: MeI; Yield: 3.56 g; 82 %; Purity (cap. GC): 96 %.
IR(cm-1): 3085, 3062, 3027, 2964, 2932, 2806, 1716, 1603, 1496, 1472, 1455, 1418, 1378, 1358, 1329, 1220,
1187, 1139, 884, 751, 700; 1H-NMR (): 1.01 (d, J = 6.8, CH3), 2.14 (t, J = 11.6, 1H), 2.30–2.49 (m, 2H),
2.53–2.73 (m, 4H), 2.77–2.88 (m, 2H), 3.12–3.22 (m, 2H), 7.15–7.37 (m, 5HAr);
13C-NMR(ppm): 11.71,
33.87, 40.64, 44.00, 53.64, 58.90, 60.69, 125.97, 128.25, 128.49, 139.83, 210.56.
4. ()-3-Ethyl-1-phenethyl-piperidin-4-one (3.2).
From imine 2 (5.69 g, 20 mmol); Alkyl halide: EtI; Yield: 3.93 g; 85 %; Purity (cap. GC): 95 %. IR(cm-1):
3085, 3063, 3027, 2952, 2934, 1717, 1604, 1501, 1468, 1451, 1422, 1362, 1333, 1219, 1177, 1135, 1079, 1034,
887, 750, 698; 1H-NMR (): 0.89 (t, J = 6.8, CH3), 1.23–1.33 (m, 1H), 1.74–1.90 (m, 1H), 2.19 (t, J = 10.8, 1H),
2.37–2.51 (m, 4H), 2.67–2.76 (m, 2H), 2.80–3.14 (m, 2H), 3.09–3.15 (m, 2H), 7.17–7.34 (m, 5HAr);
13C-NMR(ppm): 11.18, 21.1, 33.89, 39.33, 51.11, 54.61, 61.35, 125.89, 128.01, 128.59, 139.87, 210.93.
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5. ()-3-i-Propyl-1-phenethyl-piperidin-4-one (3.3).
From imine 2 (5.69 g, 20 mmol); Alkyl halide: i-PrI; Yield: 3.88 g; 79 %; Purity (cap. GC): 95 %.
IR(cm-1): 3082, 3062, 3022, 2965, 2930, 1718, 1600, 1502, 1479, 1455, 1418, 1378, 1371, 1358, 1325, 1220,
1187, 1133, 747, 698; 1H-NMR (): 0.91 (dd, J1 = 1.8, J2 = 6.8, 2 CH3), 1.55–1.85 (m, 1H), 2.22–2.26 (m,
2H), 2.46 (t, J = 6.2, 2H), 2.57–2.75 (m, 3H), 2.81–2.96 (m, 4H), 7.15–7.38 (m, 5HAr);
13C-NMR(ppm):
19.16, 20.67, 25.64, 33.90, 40.71, 53.66, 55.26, 56.17, 59.19, 125.94, 128.21, 128.47, 139.88, 210.71.
6. ()-3-Butyl-1-phenethyl-piperidin-4-one (3.4).
From imine 2 (5.69 g, 20 mmol); Alkyl halide: BuBr; Yield 3.23 g; 83 %; Purity (cap. GC): 97 %.
IR/(cm-1): 3086, 3063, 3027, 2955, 2931, 2860, 1717, 1603, 1497, 1468, 1455, 1417, 1358, 1330, 1224, 1182,
1138, 1080, 1031, 887, 751, 700; 1H-NMR (): 0.89 (t, J = 7.0, CH3), 1.21–1.36 (m, 5H), 1.71–1.92 (m, 1H),
2.24 (t, J = 10.8, 1H), 2.35–2.57 (m, 4H), 2.65–2.80 (m, 2H), 2.82–3.10 (m, 2H), 3.13–3.17 (m, 2H),
7.17–7.34 (m, 5HAr):
13C-NMR/(ppm): 13.86, 22.67, 26.88, 29.21, 34.00, 40.82, 49.58, 53.73, 58.94, 59.16,
126.08, 128.36, 128.62, 139.98, 210.85.
7. ()-1,3-Diphenethyl-piperidin-4-one (3.6).
From imine 2: 5.69 g, 20 mmol; Alkyl halide: PhenBr; Yield 3.92 g; 85 %; Purity (cap. GC): 94 %.
IR(cm-1): 3080, 3058, 3021, 2960, 2952, 2930, 2858, 1711, 1598, 1497, 1473, 1450, 1375, 1362, 1329, 1277,
1257, 1220, 1165, 1145, 1084, 1044, 1034, 999, 890, 771, 751, 740, 720, 701; 1H-NMR (): 2.13–2.42 (m,
5H); 2.66–2.78 (m, 1H); 2.84–2.95 (m, 2H); 3.31 (d, J = 12.5, 1H); 3.49 (d, J = 12.9; 1H); 3.61–3.68 (m, 5H);
7.22–7.32 (m, 10HAr);
13C-NMR(ppm): 32.21; 31.93; 33.02; 40.12; 51.08; 53.23; 56.14; 58.25; 124.69;
125.04; 127.11; 127.10; 127.79; 138.22; 138.97; 209.01.
8. 3-Butyl-1-phenethyl-N-phenylpiperidin-4-amine (5.4).
Typical procedure for the preparation of 3-alkyl-4-anilinopiperidines 5.1–5.6, is illustrated on 3-bu-
tyl-4-anilinopiperidine (5.4). The method is directly applicable to all the other anilinopiperidines 5.1–5.6.
A single necked flask equipped with a Dean and Stark adapter was purged with Ar and charged with
piperidone 3.4 (3.0 g, 0.0116 mol), aniline (2.15 g, 2 eq.), anh. ZnCl2 (0.16 g, 0.1 eq.) and xylene (100 mL).
The mixture was stirred and refluxed for 36 h, under Ar, with azeotropic water separation, then cooled to  20
ºC and filtered under Ar. The filtrate was concentrated on a rotatory evaporator, using a moisture absorbing
filter with 4A sieves, to prevent imine hydrolysis. The crude imine 4.4 was obtained as a dark-colored oil,
containing residual aniline which was used directly in the next step. IR (cm-1): 1660 (band characteristic of
the imine group). A two necked flask equipped with a pressure-equalizing dropping funnel and a reflux con-
denser capped with a mineral oil bubbler (with gas inlet) was purged with Ar and charged with abs. THF (50
mL) and LiAlH4 (0.44 g, 4 eq.). The mixture was stirred and heated to reflux, then imine 4.4 in THF (10 mL)
was added dropwise, over 10 min (H2 evolution). After 10 h (the Ar atmosphere was maintained), the mixture
was cooled to  20 ºC, EtOAc (5 mL, 5 eq.) was added dropwise (H2 evolution), followed by 10 % HCl (30
mL). The mixture was concentrated using a rotatory evaporator, the residue alkalized with 10 % NaOH to pH
> 12, extracted (CH2Cl2, 3  50 mL), the combined extracts dried (anh. K2CO3) and concentrated. The excess
aniline was removed under reduced pressure (0.5 mm Hg, 50 ºC, 30 min) and the residue chromatographed
on an Al2O3 column (120 g of Al2O3) using hexane: EtOAc gradient: 99/1, 98/2, etc. The less polar cis iso-
mer 5.4cis eluted first followed by the trans isomer 5.4trans.
8.1. ()-5.4cis. Yield: 1.65 g, 42 % (pale yellow viscous oil). Purity (cap. GC) = 98 %. IR(cm-1): 3410,
3085, 3055, 3026, 2952, 2929, 2858, 2803, 2767, 1601, 1503, 1467, 1455, 1434, 1376, 1317, 1255, 1205,
1180, 1156, 1128, 1104, 1076, 1030, 995, 749, 696; 1H-NMR (): 0.85 (t, J = 6.6, CH3), 1.23–1.30 (m, 3
CH2), 1.71–1.78 (m, 1H), 1.87–2.07 (m, 2H), 2.29–2.49 (m, 2H), 2.53–2.61 (m, 4H), 2.82 (t, J = 8.5, 2H), 3.61
(q, J = 4.8, 1H), 3.43–3.90 (m, 1H), 6.61 (d, J = 8.0, 2HAr), 6.70 (t, J = 7.0, 1HAr), 7.12–7.34 (m, 7HAr);
13C-NMR(ppm): 14.01, 23.03, 28.99, 31.32, 34.17, 34.66, 43.51, 52.32, 53.53, 59.11, 60.34, 112.81, 116.52,
125.69, 128,06, 128.40, 129.12, 140.16, 147.72, MS (C.I.): 245 (M–91.8), 337 (M+1, 100), 393 (M+57, 12).
8.2. ()-5.4trans. Yield: 1.00 g, 26 % (pale yellow viscous oil). Purity (cap. GC) = 98 %. IR(cm-1): 3376,
3085, 3055, 3026, 2952, 2929, 2858, 1602, 1501, 1467, 1455, 1376, 1320, 1270, 1181, 1153, 1132, 1111, 1037,
1030, 992, 959, 868, 748, 696, 1H-NMR (): 0.87 (t, J = 6.6, CH3), 1.10–1.44 (m, 3CH2), 1.49–1.59 (m, 1H),
1.71–1.79 (m, 1H), 1.87 (m, 1H), 2.05–2.21 (m, 2H), 2.57–2.66 (m, 2H), 2.84 (t, J = 6.2, 2H), 2.93–3.15 (m, 3H),
3.42–3.80 (m, 1H), 6.58 (d, J = 8.0, 2HAr), 6.67 (t, J = 7.0, 1HAr), 7.10–7.34 (m, 7HAr).
13C-NMR(ppm): 13.91,
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22.83, 29.08, 30.20, 32.27, 33.66, 42.30, 52.49, 54.71, 58.30, 60.43, 112.76, 116.60, 125.79, 128.16, 128.48,
129.07, 140.21, 147.66; (MS (C.I.): 245 (M–91, 10), 337 (M+1, 100), 393 (M+57, 10).
9. 3-Methyl-1-phenethyl-N-phenylpiperidin-4-amine (5.1).
From piperidone 3.1 (4.0 g, 0.0184 mol).
9.1. ()-5.1cis. Yield: 2.77 g, 51 % (pale yellow viscous oil). Purity (cap. GC) = 98 %. IR/(cm-1): 3395,
3085, 3056, 3025, 2947, 1602, 1505, 1467, 1455, 1436, 1373, 1354, 1322, 1271, 1179, 1126, 1108, 1092,
1070, 1030, 992, 977, 867, 695; 1H-NMR (): 0.99 (d, J = 7.0, CH3), 1.80 (quint, J = 4.6, CH2), 2.12–2.30 (m,
1H), 2.48–2.68 (m, 6H), 2.81 (t, J = 8.4, 2H) 3.52–3.55 (m, 2H), 6.59–6.71 (m, 3HAr), 7.13–7.33 (m, 7HAr).
13C-NMR(ppm): 11.57, 29.00, 33.65, 40.26, 49.28, 50.10, 54.39, 60.64, 112.93, 116.74, 125.85, 128.22,
128.56, 129.18, 140.35, 147.17; MS (C.I.): 203 (M–91, 10), 295 (M+1, 100).
9.2. ()-5.1trans. Yield: 1.13 g, 21 % (pale yellow viscous oil). Purity (cap. GC) = 98 %. IR(cm-1):
3395, 3085, 3055, 3025, 2947, 1602, 1505, 1466, 1455, 1437, 1371, 1354, 1322, 1272, 1181, 1126, 1107,
1090, 1070, 1030, 990, 977, 869, 695; 1H-NMR (): 1.01 (d, J = 6.6, CH3), 1.37–1.50 (m, 1H), 1.58–1.76 (m,
1H), 1.86 (t, J = 10.8, 1H), 2.03–2.21 (m, 2H), 2.57 (dd, J1 = 1.6, J2 = 7.0, 1H), 2.62 (d, J = 4.6, 1H),
2.78–2.92 (m, 3H), 2.98–3.06 (m, 2H), 3.18–3.38 (m, 1H), 6.56–6.69 (m, 3HAr), 7.12–7.33 (m, 7HAr);
13C-NMR(ppm): 16.62, 32.59, 33.77, 37.84, 53.00, 56.52, 60.41, 60.91, 112.86, 116.74, 125.93, 128.29,
128.60, 129.20, 140.31, 147.82; MS (C.I.); 203 (M–91, 10) 295 (M+1, 100), 351 (M+57, 10).
10. 3-Ethyl-1-phenethyl-N-phenylpiperidin-4-amine (5.2).
From piperidone 3.2 (2.0 g, 0.00864 mol).
10.1. ()-5.2cis. Yield: 1.02 g, 38 % (pale yellow viscous oil). Purity (cap. GC) = 98 %. IR(cm-1): 3418,
3084, 3053, 3025, 2956, 2874, 2803, 2768, 1601, 1504, 1467, 1455, 1433, 1373, 1316, 1253, 1180, 1124,
1100, 1075, 1046, 1030, 992, 748, 695, 506; 1H-NMR (): 0.89 (t, CH3, J = 7.4), 1.39 (quint, CH2, J = 7.4),
1.62–1.75 (m, 1H), 1.86–1.91 (m, 2H), 2.21–2.48 (m, 3H), 2.54–2.64 (m, 3H), 2.82 (t, J = 7.8, 2H), 3.57–3.70
(m, 2H), 6.59–6.70 (m, 3HAr), 7.09–7.38 (m, 7HAr);
13C-NMR(ppm): 11.57, 21.25, 29.00, 33.65, 40.26,
49.28, 50.10, 54.39, 60.64, 112.93, 116.74, 125.85, 128.22, 128.56, 129.18, 140.35, 147.17; MS (C.I.): 217
(M–91, 15), 309 (M+1, 100), 365 (M+57, 10).
10.2. ()-5.2trans. Yield: 0.71 g, 27 % (pale yellow viscous oil). Purity (cap. GC) = 98 %. IR(cm-1):
3397, 3085, 3054, 3025, 2958, 2936, 2875, 2804, 2767, 1602, 1505, 1466, 1455, 1435, 1376, 1320, 1276,
1181, 1154, 1131, 1110, 1072, 1030, 748, 695; 1H-NMR (): 0.89 (t, CH3, J = 7.4), 1.11–1.25 (m, 1H),
1.36–1.49 (m, 2H), 1.73–1.88 (m, 2H), 1.99–2.16 (m, 2H), 2.53–2.63 (m, 2H), 2.77–2.84 (m, 2H), 2.91–3.11
(m, 3H), 6.52–6.67 (m, 3HAr), 7.10–7.32 (m, 7HAr);
13C-NMR(ppm): 11.22, 23.13, 32.30, 33.61, 43.86,
52.55, 54.33, 57.79, 60.49, 112.67, 116.56, 125.87, 128.21, 128.52, 129.12, 140.18, 147.68; MS (C.I.): 217
(M–91, 15), 309 (M+1, 100), 365 (M+57, 10).
11. 3-i-Propyl-1-phenethyl-N-phenylpiperidin-4-amine (5.3).
From piperidone 3.3 (3.0 g, 0.0122 mol).
11.1. ()-5.3cis. Yield: 1.13 g, 29 % (pale yellow viscous oil). Purity (cap. GC) = 98 %. IR(cm-1): 3425,
3053, 3025, 2953, 2870, 1601, 1505, 1469, 1455, 1430, 1383, 1365, 1350, 1314, 1249, 1214, 1179, 1147,
1104, 1085, 1030, 1011, 747, 693; 1H-NMR (): 0.89 (d, J = 6.0, CH3), 0.95 (d, J = 6.2, CH3), 1.53–1.73 (m,
3H), 1.94 (qd, Jq = 11.4, Jd = 2.2, 2H), 2.17 (td, Jd = 2.4, Jt = 12.8, 1H), 2.56–2.70 (m, 2H), 2.71–2.88 (m, 3H),
2.98–3.06 (m, 1H), 3.80 (broad. s, 2H), 6.58–6.70 (m, 3HAr), 7.12–7.33 (m, 7HAr);
13C-NMR(ppm): 20.34,
20.94, 27.33, 29.10, 33.67, 46.21, 46.30, 47.87, 52.89, 61.03, 112.78, 116.76, 126.03.
11.2. ()-5.3trans. Yield: 0.92 g, 23 % (pale yellow viscous oil). Purity (cap. GC): 98 %. IR/(cm-1): 3392,
3053, 3025, 2955, 2871, 1602, 1505, 1466, 1454, 1434, 1369, 1353, 1318, 1283, 1233, 1181, 1154, 1137, 1123,
1071, 1031, 992, 749, 699; 1H-NMR (): 0.84 (d, J = 7.0, CH3), 0.98 (d, J = 7.0, CH3), 1.36–1.59 (m, 2H), 1.93 (d,
J = 11.2, 1H), 2.04 (d, J = 10.4, 1H), 2.14–2.23 (m, 2H), 2.56–2.63 (m, 2H), 2.79–2.87 (m, 2H), 2.93–3.00 (m, 2H),
3.28 (br. s, 2H), 6.57–6.69 (m, 3HAr), 7.12–7.34 (m, 7HAr);
13C-NMR (ppm): 17.17, 20.94, 25.86, 32.54, 33.85,
47.30, 51.80, 52.75, 53.35, 60.89, 112.85, 116.80, 126.05, 128.40, 128.69, 129.36, 140.36, 147.64.
12. 3-Benzyl-1-phenethyl-N-phenylpiperidin-4-amine (5.5).
From piperidone 3.5 (2.0 g, 0.00681 mol).
12.1. ()-5.5cis. Yield: 1.02 g, 40 % (pale yellow viscous oil). Purity (cap. GC): 98 %. IR(cm-1): 3401,
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3084, 3059, 3025, 2942, 2859, 2802, 2767, 1602, 1504, 1468, 1454, 1434, 1372, 1314, 1288, 1255, 1179,
1154, 1120, 1071, 1030, 1004, 983, 910, 699, 506; 1H-NMR (): 1.73–1.88 (m, 3H), 2.28–2.82 (m, 10H),
3.45–3.60 (m, 1H), 3.67 (br. s, 1H), 6.58–6.74 (m, 3HAr), 7.00–7.34 (m, 12HAr);
13C-NMR (ppm): 28.72,
33.54, 40.49, 50.47, 50.68, 53.22, 54.20, 60.26, 113.29, 117.00, 125.58, 125.78, 128.01, 128.12, 128.53,
129.03, 129.12, 140.36, 140.55, 146.80; MS (C.I.): 280 (M–90, 25), 371 (M+1, 100), 427 (M+57, 20).
12.2. ()-5.5trans. Yield: 0.52 g, 0.21 % (pale yellow viscous oil). Purity (cap. GC): 98 %. IR (cm-1):
3402, 3084, 3058, 3025, 2942, 2858, 2804, 2766, 1601, 1505, 1497, 1468, 1454, 1435, 1375, 1319, 1270,
1218, 1181, 1154, 1118, 1072, 1031, 748, 699; 1H-NMR (): 1.44 (qt, Jt = 1.6, Jq = 11.6, 1H), 1.84–1.92 (m,
2H), 2.13 (qd, Jd = 2.6, Jq = 11.2, 2H), 2.40–2.58 (m, 3H), 2.65–2.77 (m, 2H), 2.85–2.97 (m, 2H), 3.11 (dd, Jd1
= 3, Jd2 = 13.4, 2H), 3.35–3.55 (br. s, 1H), 6.58 (d, J = 8.6, 2HAr), 6.68 (t, J = 8.2, 1HAr), 7.08–7.38 (m,
12HAr);
13C-NMR (ppm): 32.10, 33.64, 37.29, 43.88, 52.30, 54.40, 57.83, 60.30, 113.00, 116.95, 125.83,
125.86, 128.16, 128.21, 128.54, 129.04, 129.22, 140.00, 140.24, 147.47; MS (C.I.): 279 (M–91, 30), 371
(M+1, 100), 428 (M+58, 20).
13. 1,3-Diphenethyl-N-phenylpiperidin-4-amine (5.6).
From piperidone 3.6 (2.0 g, 0.0065 mol).
13.1 ()-5.6cis. Yield: 0.78 g (31 %) (pale yellow viscous oil). Purity (cap. GC): 98 %. IR (cm-1): 3402,
3084, 3058, 3025, 2945, 2858, 2804, 1604, 1514, 1501, 1465, 1442, 1381, 1330, 1277, 1220, 1182, 1150, 1122,
1062, 1030, 755, 700; 1H-NMR (): 1.33–1.69 (m), 1.86–1.97 (m), 2.05–2.18 (m), 2.35 (s, NH), 2.54–2.63 (m),
2.65–2.73 (m), 2.78–2.82 (m), 2.98–3.31 (m), 6.51–6.68 (m, 2HAr), 7.05–7.18 (m, 13HAr);
13C-NMR (ppm):
28.73, 33.18, 33.41, 37.74, 49.67, 50.14, 54.49, 60.22, 113.01, 116.84, 125.50, 125.81, 128.07, 128.11, 128.15,
128.47, 129.11, 140.09, 142.00, 147.01; MS (C.I.): 441 (M+57, 10 %), 385 (M+1, 100 %).
13.2 ()-5.6trans. Yield: 0.48 g (19 %) (pale yellow viscous oil). Purity (cap. GC): 98 %. IR (cm-1): 3402,
3084, 3058, 3025, 2945, 2858, 2804, 1605, 1514, 1501, 1464, 1440, 1382, 1331, 1277, 1220, 1177, 1150, 1120,
1062, 1029, 748, 702; 1H-NMR (): 1.45–1.63 (m), 1.84–1.97 (m), 2.01–2.21 (m), 2.40 (s, NH), 2.55–2.64 (m),
2.65–2.73 (m), 2.78–2.82 (m), 3.00–3.31 (m), 6.51–6.68 (m, 2HAr), 7.05–7.18 (m, 13HAr):
13C-NMR (ppm):
29.05, 33.38, 33.49, 37.61, 49.70, 50.11, 54.55, 60.27, 113.09, 116.88, 125.48, 125.83, 128.06, 128.14, 128.19,
128.52, 129.06, 140.12, 142.08, 147.04; MS (C.I.): 441 (M+57, 14 %), 385 (M+1, 100 %).
14. A typical procedure for the preparation of the 3-alkyl-4-anilidopiperidines 6.1–6.6.
This procedure is illustrated on compound ()-6.1cis and it is directly applicable to all the other
anilidopiperidines 6.1–6.6. All the yields and the m.p.(dec.) values refer to the monooxalate salts. All the
spectral data refer to the free bases.
14.1. ()-cis-N-(3-Methyl-1-phenethylpiperidin-4-yl)-N-phenylpropionamide (6.1cis). A three necked
flask, equipped with a pressure-equalizing dropping funnel, reflux condenser capped with a mineral oil
bubbler and a thermometer was flushed with Ar and charged with anilinopiperidine 5.1cis (1.47 g; 5 mmol),
Et3N (0.35 mL; 2.5 mmol) and CH2Cl2 (15 mL). The mixture was cooled (–5–0 ºC), propionyl chloride (0.9
mL; 10 mmol/5 mL CH2Cl2) added dropwise over 5 min at 0–5 ºC and the stirring continued for 4 h at 20 ºC.
The hydrochloride salts form a voluminous precipitate. Upon addition of MeOH (5 mL), the precipitate dis-
solved, the mixture was stirred for 10 min and then poured into aqueous K2CO3, (5 g/50 mLH2O). The layers
were separated, the aqueous layer was extracted with CH2Cl2 ( 2  15 mL) and the combined organic layers
were dried (anh. K2CO3) and concentrated (rotatory evaporator). The residual oil was dissolved in dry
i-PrOH (5 mL), added to anh. oxalic acid solution (0.55 g; 6.1 mmol/5 mL i-PrOH) and the mixture is left to
crystallize at –20 ºC (12 h). The crystallized salt was filtered off, washed with ether and dried under vacuum
(40 ºC, 2 h, 0.1 Torr). Yield: 2.07 g (94 %); m.p. (dec.): 162–163 ºC (Lit.9b 163–164 ºC). The purity of the free
base (liberated from the oxalate salt), cap. GC > 99 %; pale yellow viscous oil.
Free base: IR (cm-1): 3455, 3061, 3027, 2938, 2804, 2773, 1658, 1594, 1494, 1455, 1374, 1273, 1246, 1158,
1122, 1093, 1074, 1050, 1030, 1008, 985, 750, 701; 1H-NMR (): 1.10 (t, J = 7.6, CH3), 1.11 (d, J = 7.0, CH3),
1.21–1.31 (m, 1H), 1.44 (td, Jd = 4.2, Jt = 12.2, 1H), 1.94 (q, J = 7.2, CH2), 2.06 (dd, J1 = 3.2, J2 = 11.6, 1H), 2.28
(d, J = 9.0, 1H), 2.40–2.58 (m, 2H), 2.66–2.82 (m, 5H), 4.41 (dt, Jt = 4.4, Jd = 12.6, C4–H), 7.05–7.35 (m, 10HAr);
13C-NMR (ppm): 9.56, 13.88, 26.33, 28.93, 31.21, 33.61, 54.10, 57.46, 59.36, 60.25, 125.79, 127.89, 128.18,
128.67, 128.83, 129.00, 130.33, 130.69, 140.60, 174.33; MS (C.I.): 259 (M–91, 45), 351 (M+1, 100).
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14.2. ()-trans-N-(3-Methyl-1-phenethylpiperidin-4-yl)-N-phenylpropionamide (6.1trans).
From ()-5.1trans (1.0 g, 0.0034 mol); Yield: = 1.47 g, 98 %; m.p. (dec.): 157–158 ºC (Lit.9b 159–160
ºC). Free base: IR (cm-1): 3061, 3025, 2940, 2801, 1658, 1594, 1495, 1455, 1372, 1279, 1241, 1160, 1093,
1070, 1053, 1030, 1014, 985, 751, 702; 1H-NMR (): 1.01 (d, J = 7.6, CH3), 1.04 (t, J = 6.2, CH3), 1.44 (qd, Jd
= 3.2, Jq = 12.2, 1H), 1.69–1.77 (m, 2H), 1.96 (q, J = 7.4, CH2), 2.12 (td, Jd = 2.4, Jt = 11.8, 1H), 2.47–2.55
(m, 2H), 2.71–2.77 (m, 2H), 2.95–3.01 (m, 2H), 4.58 (t, Jt = 11.4, C4–H), 7.06–7.45 (m, 10 HAr);
13C-NMR
(ppm): 9.69, 16.35, 28.44, 30.41, 33.70, 34.00, 53.11, 57.25, 60.34, 60.74, 125.98, 128.21, 128.32, 128.58,
129.38, 129.58, 130.98, 140.14, 174.24; MS (C.I.): 259 (M–91, 45), 351 (M+1, 100).
15.1. ()-cis-N-(3-Ethyl-1-phenethylpiperidin-4-yl)-N-phenylpropionamide (6.2cis).
From ()-5.2cis. (0.9 g, 0.0029 mol); Yield: 1.65 g, 95 %; m.p. (dec.): 142–144 ºC.
Free base: IR (cm-1): 3061, 3026, 2958, 1657, 1595, 1495, 1454, 1374, 1273, 1246, 1158, 1125, 1092,
1056, 1032, 985, 751, 702; 1H-NMR (): 0.95 (t, J = 7.4, CH3), 1.01 (t, J = 7.2, CH3), 1.21–1.32 (m, 1H), 1.39
(dd, J1 = 4.2, J2 = 12, 1H), 1.52–1.64 (m, 2H), 1.94 (q, J = 7.2, CH2), 2.04–2.14 (m, 2H), 2.38–2.60 (m, 3H),
2.67–2.81 (m, 3H), 3.02 (dd, J1 = 2.4, J2 = 11.8, 1H), 4.40 (dt, Jt = 4.6, Jd = 12.4, C4–H), 7.05–7.36 (m,
10HAr);
13C-NMR (ppm): 9.53, 12.13, 18.74, 26.97, 28.99, 33.67, 38.15, 54.10, 58.19, 60.25, 125.74, 127.85,
128.16, 128.60, 128.80, 128.98, 130.13, 130.71, 140.50, 140.72, 174.39; MS (C.I.): 365 (M+1, 100).
15.2 ()-trans-N-(3-Ethyl-1-phenethylpiperidin-4-yl)-N-phenylpropionamide (6.2trans).
From ()-5.2trans. (0.5 g, 0.00162 mol). Yield: 0.74 g, 97 %; m.p. (dec.): 135–136 ºC.
Free base: IR (cm-1): 3061, 3026, 2936, 2877, 1657, 1595, 1495, 1462, 1377, 1315, 1260, 1240, 1133,
1076, 1047, 744, 703; 1H-NMR (): 0.94 (t, J = 7.2, CH3), 1.02 (t, J = 7.4, CH3), 1.21–1.31 (m, 1H),
1.42–1.50 (m, 2H), 1.70–1.81 (m, 3H), 1.95 (q, J = 7.6, CH2), 2.09 (td, Jd = 2.2, Jt = 12, 1H), 2.48–2.60 (m,
2H), 2.74 (t, J = 6.6, 2H), 2.99 (d, J = 11.2, 1H), 3.13 (d, J = 10, 1H), 4.61 (td, Jd = 3, Jt = 12, C4–H),
7.06–7.42 (m, 10HAr);
13C-NMR (ppm): 9.56, 11.09, 22.83, 28.33, 30.32, 33.61, 40.30, 52.82, 55.44, 58.08,
60.45, 125.87, 128.11, 128.21, 128.47, 129.05, 129.33, 129.47, 130.95, 138.56, 140.03, 174.11; MS (C.I.):
273 (M–91, 30), 365 (M+1, 100), 407 (M+43, 20).
16.1 ()-cis-N-(3-isopropyl-1-phenethylpiperidin-4-yl)-N-phenylpropionamide (6.3cis).
From ()-5.3cis. (1.0 g, 0.0031 mol). Yield: 1.36 g, 94 %; m.p. (dec.): 122–124 ºC.
Free base: IR (cm-1): 3061, 3030, 2951, 2944, 1652, 1595, 1540, 1495, 1461, 1455, 1397, 1382, 1259,
1181, 1141, 1130, 1074, 1050, 974, 940, 900, 751, 703; 1H-NMR (): 1.00 (t, J = 7.2, CH3), 1.01 (d, J = 6.8,
CH3), 1.11 (d, J = 6.4, CH3), 1.16–1.68 (m, 3H), 1.87–1.98 (m, CH2), 2.00–2.11 (m, 2H), 2.14–2.24 (m, 2H),
2.35–2.57 (m, 2H), 2.67–2.76 (m, 2H), 4.60 (quint, J = 5.0, C4–H), 7.04–7.43 (10HAr);
13C-NMR (ppm):
9.60, 20.92, 24.49, 26.06, 28.48, 29.08, 33.39, 42.39, 52.57, 54.00, 60.56, 125.90, 128.09, 128.27, 128.63,
129.02, 131.05, 140.43, 141.43, 174.75; MS (C.I.): 287 (M–91, 15), 379 (M+1, 100), 422 (M+44, 5).
16.2 ()-trans-N-(3-Isopropyl-1-phenethylpiperidin-4-yl)-N-phenylpropionamide (6.3trans).
From ()-5.3trans. (0.7 g, 0.0022 mol). Yield: 0.98 g, 95 %; m.p. (dec.): 115–117 ºC.
Free base: IR (cm-1): 3060, 3028, 2956, 2938, 1652, 1595, 1541, 1495, 1463, 1455, 1391, 1372, 1255,
1181, 1142, 1125, 1071, 1049, 974, 943, 898, 752, 703; 1H-=NMR (): 0.98 (d, J = 6.8, CH3), 1.01 (d, J = 6.8,
CH3), 1.02 (t, J = 7.4, CH3), 1.15–1.33 (m, 1H), 1.48 (td, Jd = 4.0, Jt = 12.4, 2H), 1.70–1.82 (m, 2H), 1.91 (q, J
= 5.2, CH2), 1.97–2.16 (m, 2H), 2.46–2.62 (m, 2H), 2.64–2.80 (m, 2H), 2.88–3.04 (m, 2H), 4.83 (td, Jd = 3.6,
Jt = 12.0, C4–H), 7.04–7.43 (m, 10HAr);
13C-NMR (ppm): 9.64, 16.78, 21.00, 25.89, 28.39, 30.55, 33.72,
43.43, 53.00, 60.72, 125.88, 128.14, 128.25, 128.49, 129.27, 131.18, 138.61, 140.10, 174.02; MS (C.I.): 287
(M–91, 15), 379 (M+1, 100).
17.1. ()-cis-N-(3-Butyl-1-phenethylpiperidin-4-yl)-N-phenylpropionamide (6.4cis).
From ()-5.4cis: (1.5 g, 0.0045 mol). Yield: 2.08 g, 96 %; m.p. (dec.): 97–98 ºC).
Free base: IR (cm-1): 3462, 3065, 3026, 2955, 2868, 2797, 1655, 1595, 1495, 1451, 1421, 1375, 1343,
1326, 1305, 1274, 1246, 1159, 1127, 1091, 1049, 1030, 768, 745, 704, 594, 507; 1H-NMR (): 0.92 (t, J = 7,
CH3), 1.01 (t, J = 7.6, CH3), 1.21–1.49 (m), 1.97 (q, J = 6, CH2), 2.04–2.15 (m), 2.43–2.61 (m), 2.66–2.78
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(m), 2.93 (t, J = 2.5, 1H), 2.99 (t, J = 2.4, 1H), 4.38 (dt, Jd = 12.4, Jt = 4.5, C4–H), 7.0–7.42 (m, 10HAr);
13C-NMR (ppm): 9.52, 14.10, 22.90, 25.69, 27.01, 28.99, 30.06, 33.63, 36.49, 54.11, 55.01, 58.15, 60.16,
125.77, 127.85, 128.15, 128.61, 128.81, 128.96, 130.13, 130.71, 140.56, 140.78, 174.40; MS (C.I.): 393
(M+1, 100).
17.2. ()-trans-N-(3-Butyl-1-phenethylpiperidin-4-yl)-N-phenylpropionamide (6.4trans).
From ()-5.4trans: (0.8 g, 0.0024 mol). Yield: 1.13 g; 98 %; m.p. (dec.): 90–92 ºC.
Free base: IR (cm-1): 3061, 3026, 2952, 2932, 1658, 1595, 1542, 1495, 1455, 1390, 1377, 1257, 1240,
1137, 1076, 746, 703; 1H-NMR (): 0.94 (t, J = 7.0, CH3), 1.03 (t, J = 7.4, CH3), 1.16–1.55 (m, 7H), 1.77 (t, J
= 11.0, 3H), 1.96 (q, J = 7.4, CH2), 2.11 (t, J = 10.2, 1H), 2.48–2.60 (m, 2H), 2.70–2.78 (m, 2H), 2.99 (d, J =
11.2, 1H), 3.13 (d, J = 9.8, 1H), 4.61 (t, J = 7.0, C4–H), 7.06–7.42 (m, 10HAr);
13C-NMR (ppm): 9.64, 14.00,
22.94, 28.33, 28.90, 29.81, 30.35, 33.58, 38.84, 52.82, 55.57, 58.57, 60.43, 125.87, 126.11, 128.21, 128.47,
129.05, 129.27, 129.45, 130.91, 138.60, 140.03, 174.15; MS (C.I.): 302 (M–90, 80) 393 (M+1, 100) 436
(M+44, 80) 449 (M+57, 40).
18.1. ()-cis-N-(3-Benzyl-1-phenethylpiperidin-4-yl)-N-phenylpropionamide (6.5cis).
From ()-5.5cis (0.90 g, 0.0024 mol). Yield: 1.18 g, 95 %; m.p. (dec.): 129–131 ºC.
Free base: IR (cm-1): 3083, 3061, 3024, 2937, 2860, 1657, 1595, 1495, 1453, 1319, 1262, 1180, 1139,
1095, 1070, 1037, 903, 749, 734, 701;1H-NMR (): 1.07 (t, J = 7.6, CH3), 1.26–1.34 (m, 1H), 1.51 (qd, Jd =
4.2, Jq = 12.6, 1H), 2.00 (q, J = 6.0, CH2), 1.94–2.09 (m, 2H), 2.25–2.40 (m, 1H), 2.42–2.52 (m, 1H),
2.55–2.67 (m, 3H), 2.73–2.88 (m, 4H), 4.49 (dt, Jt = 3.4, Jd = 12.4, C4–H), 7.07–7.35 (m, 10HAr);
13C-NMR
(ppm): 9.64, 26.82, 28.95, 32.17, 33.43, 38.78, 53.68, 53.97, 58.19, 59.83, 125.45, 125.63, 127.81, 127.98,
128.52, 128.83, 128.96, 129.16, 129.98, 130.54, 140.49, 141.16, 174.39; MS (C.I.): 335 (M–91, 15), 427
(M+1, 100).
18.2. ()-trans-N-(3-Benzyl-1-phenethylpiperidin-4-yl)-N-phenylpropionamide (6.5trans).
From ()-5.5trans (0.40 g, 0011 mol); Yield: 0.55 g, 97 %; m.p. (dec.): 125–126 ºC).
Free base: IR (cm-1): 3085, 3061, 3026, 2937, 2860, 2804, 1658, 1595, 1495, 1453, 1315, 1259, 1177,
1137, 1092, 1073, 1032, 911, 749, 734, 701; 1H-NMR (): 1.04 (t, J = 7.6, CH3), 1.56 (td, Jd = 4.0, Jt = 12.4,
1H), 1.83 (t, J = 10.6, 2H), 1.99 (q, J = 7.6, CH2), 2.12 (td, Jd = 1.6, Jt = 12.0, 1H), 2.34–2.51 (m, 4H),
2.53–2.69 (m, 2H), 2.78 (dd, J1 = 2.2, J2 = 10.2, 1H), 3.00 (d, J = 9.8, 1H), 3.24 (dd, J1 = 2.2, J2 = 14, 1H),
4.75 (t, J = 10.0, C4–H), 7.04–7.45 (m, 15 HAr):
13C-NMR (ppm): 9.67, 28.50, 30.65, 33.49, 36.82, 40.02,
52.69, 58.00, 58.41, 60.23, 125.90, 126.91, 128.25, 128.36, 128.49, 128.62, 129.43, 130.96, 138.76, 139.65,
139.99, 174.46; MS (C.I.): 335 (M–91, 10), 427 (M+1, 100).
19.1. ()-cis-N-(1,3-Diphenethylpiperidin-4-yl)-N-phenylpropionamide (6.6cis).
From ()-5.6cis: (0.60 g, 0.0016 mol); Yield: 0.80 g; 94 %; m.p. (dec.): 119–121 ºC.
Free base: IR (cm-1): 3084, 3061, 3026, 2938, 2803, 2773, 1658, 1594, 1495, 1453, 1374, 1272, 1245,
1140, 1092, 1076, 1031, 1007, 749, 701; 1H-NMR (): 1.00 (t, J = 7.2, CH3), 1.22–1.35 (m), 1.37–1.50 (m),
1.70–1.81 (m), 1.90 (q, J = 7.4, CH2), 1.00–2.12 (m), 2.13–2.18 (m), 2.43–2.62 (m), 2.66–2.81 (m), 2.94–2.98
(m), 3.00–3.04 (m), 4.37 (dt, Jt = 4.6, Jd = 12.6, C4–H), 7.05–7.20 (m, 15HAr);
13C-NMR (ppm): 9.57, 27.02,
27.75, 28.97, 33.63, 34.24, 36.70, 53.93, 55.08, 58.33, 59.91, 125.54, 125.77, 127.84, 128.19, 128.28, 128.34,
128.60, 128.84, 129.05, 130.09, 130.58, 140.54, 140.77, 142.26, 174.46; MS (C.I.): 441 (M+1,100).
19.2. ()-trans-N-(1,3-Diphenethylpiperidin-4-yl)-N-phenylpropionamide (6.6trans).
From ()-5.6trans: (0.40 g, 0.0010 mol); Yield: 0.43 g; 97 %. m.p. (dec.): 110–112 ºC.
Free base: IR (cm-1): 3084, 3061, 3026, 2938, 2811, 1658, 1594, 1495, 1452, 1370, 1269, 1251, 1141,
1095, 1080, 1032, 1004, 749, 701; 1H-NMR (): 1.00 (t, J = 7.6, CH3), 1.25–1.41 (m), 1.49–1.80 (m), 1.90 (q,
J = 8.0, CH2), 2.04–2.19 (m), 2.48–2.63 (m), 2.68–2.80 (m), 2.94–3.00 (m), 3.22–3.28 (m), 4.64 (td, Jd = 4, Jt
= 11, C4–H), 7.05–7.20 (m, 15HAr);
13C-NMR (ppm): 9.61, 25.93, 27.02, 30.67, 32.05, 33.69, 35.51, 52.17,
54.22, 57.83, 59.07, 125.51, 125.81, 127.79, 128.29, 128.30, 128.41, 128.66, 128.89, 129.05, 130.10, 130.61,
140.55, 140.81, 142.32, 174.51; MS (C.I.): 441 (M+1, 100).
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Razvijen je op{ti metod za sintezu 3-alkil analoga fentanila (tj. cis i trans 3-alkil-4-ani-
lidopiperidina 6.1–6.6) u pet faza. Polazni N-fenetil-4-piperidon 1 prvo je preveden u ciklo-
heksiliminski derivat 2, -deprotonovan butillitijumom, a postali iminski anjon efikasno
monoalkilovan primarnim i sekundarnim alkilhalogenidima. Posle blage kisele hidrolize,
nastali 3-alkil-4-piperidoni 3.1–3.6 izolovani su u dobrim prinosima (79–85 %), zatim konde-
nzovani sa anilinom do imina 4.1–4.6. Redukcijom ovih imina (LiAlH4/THF) dobijene su cis/trans
smese 3-alkil-4-anilinopiperidina 5.1–5.6. Kvantitativnim hromatografskim razdvajawem di-
jastereoizomera na stubu Al2O3 izolovani su ~isti cis 5.1–5.6 (prinos 29–51 %) i trans 5.1–5.6
(prinos 19–27 %), gde je cis/trans odnos bio u opsegu 7/3–6/4. Sinteza je zavr{ena N-acilovawem
pre~i{}enih intermedijera 5.1–5.6 pomo}u propionil-hlorida, pri ~emu su postali cis i trans
3-alkil-4-anilidopiperidini 6.1–6.6 (prinos  95 %, kao monooksalatne soli). Ni u jednoj fazi
nije poku{ano razdvajawe enantiomera. Relativna, cis/trans, stereohemija preliminarno je
odre|ena iz 1H-NMR spektra. Od dvanaest sintetisanih 3-alkil-fentanila, deset jediwewa (dva
poznata i osam novih, sva u obliku monookasalatnih soli) preliminarno su testirana kao
analgetici na pacovima, porede}i aktivnost sa fentanilom. Osim poznatog ()-cis-3-Me fenta-
nila 6.1 cis, (8  fentanil), i novog ()-cis-3-Et fentanila 6.2 cis, (1,5  fentanil), svi ostali
bili su mawe aktivni ili neaktivni. Izvedeni su odre|eni, preliminarni zakqu~ci u vezi
odnosa strukture i aktivnosti u ovoj seriji derivata.
(Primqeno 9. septembra 2003, revidirano 4. februara 2004)
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